Jaguar Health, Inc. (JAGX): Nasdaq/NYSE listing notice — Nasdaq notifies Jaguar Health of delisting due to low stock price; hearing available

Jaguar Health, Inc.

Nasdaq determined to delist JAGX effective Feb 26, 2024, as stock closed at $0.10 or less for 10 consecutive trading days.
Company may request a hearing by Feb 22, 2024, to stay suspension pending Panel decision.
Previous bid price deficiency notice was given May 2023; extension until May 6, 2024 was in effect.
No assurance that the Panel will grant an extension if hearing is requested.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Jaguar Health, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)(iii)

Exact text from the filing

February 15, 2024, the Company received a letter from the Staff notifying the Company that as of February 14, 2024, the Company's common stock had a closing bid price of $0.10 or less for 10 consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As a result, the Staff has issued a letter notifying the Company of its determination to delist the Company’s securities from Nasdaq effective as of the opening of business on February 26, 2024, unless the Company requests an appeal before

View on SEC.gov

1 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Jaguar Health, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-024908

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.